Mostafa Faisal Mohammed: Avatrombopag in Aplastic Anemia
Mostafa Faisal Mohammed Saleh, Associate professor of Clinical Hematology and HSCT at Assiut University, shared on LinkedIn:
“Our recent publication and 1st in 2026 out in Therapeutic advances in Hematology (IF 3.1)
Avatrombopag in Aplastic Anemia – Review
- Scope: 10 studies (2023–2025), diverse AA settings (frontline, R/R, elderly, liver disease)
- Efficacy: ORR 55–85%; CR up to ~30%
- Onset: Rapid responses, typically within 1–2 months
- Clinical benefit: Multilineage recovery, reduced transfusion needs
- After eltrombopag: Responses seen even in EPAG-refractory/intolerant patients
- Safety: Favorable profile; no meaningful hepatotoxicity or clonal evolution reported
- Key advantage: Suitable for patients with liver dysfunction, no dietary restrictions
Bottom line: Avatrombopag is an effective, well-tolerated TPO-RA with growing role in AA across disease stages”
Title: Efficacy and safety of avatrombopag in aplastic anemia: a comprehensive review of clinical evidence
Authors: Mostafa F. Mohammed Saleh, Abdulrahman Nasiri D, Ahmed Kotb Abdrabou, Alfadil Haroon, Hadeel Samarkandi, Hazza Alzahrani, Mahmoud Aljurf, Ali Alahmari
Read full article here.
Stay updated on the latest scientific advances in the field of aplastic anemia with Hemostasis Today.
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications
-
May 26, 2026, 15:32Haroun Gajraj: Brown Marks After Microsclerotherapy – What Every Practitioner Needs to Know
-
May 26, 2026, 15:29Jacqueline van Paassen: Lack of Essential Clinical Data in DOAC Prescriptions in Community Pharmacies